Related Experiment Video
Updated: Jul 9, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
New rationales for using TGFbeta inhibitors in radiotherapy
Kumari L Andarawewa1, Jenny Paupert, Anupama Pal
1Life Sciences Division, Berkeley, California 94720, USA.
International Journal of Radiation Biology
|December 7, 2007
Summary
Transforming growth factor beta1 (TGFbeta) plays a key role in cellular responses to ionizing radiation (IR). Inhibiting TGFbeta may enhance tumor cell radiosensitivity and protect normal tissues, improving radiotherapy.
Area of Science:
- Radiation oncology
- Molecular biology
- Cancer research
Background:
- Ionizing radiation (IR) rapidly activates transforming growth factor beta1 (TGFbeta).
- TGFbeta is a critical mediator of cellular and tissue responses to IR.
- Recent studies highlight TGFbeta's complex role in DNA damage response.
Purpose of the Study:
- To investigate the role of TGFbeta in radiosensitivity and DNA damage response.
- To explore TGFbeta as a potential target for modulating radiotherapy efficacy.
Main Methods:
- Inhibition of TGFbeta production or signaling in epithelial cells.
- Assessment of radiosensitivity and DNA damage response activation.
- Analysis of ataxia telangiectasia mutated (ATM) kinase activity.
Main Results:
- TGFbeta inhibition modulates radiosensitivity in epithelial cells.
- Inhibition of TGFbeta impedes the DNA damage response program.
- ATM kinase activity is compromised when TGFbeta is inhibited.
Conclusions:
- TGFbeta is a significant factor in the genotoxic stress program.
- Targeting TGFbeta offers a novel strategy to modulate radiotherapy.
- Identifying specific conditions for TGFbeta manipulation could enhance therapeutic index by increasing tumor radiosensitivity while protecting normal tissues.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...